Evidence map›Paper›PMID 32125786›Full record

ReviewAdvanced healthcare materials2020

Stimuli-Responsive Delivery of Growth Factors for Tissue Engineering.

Moyuan Qu, Xing Jiang, Xingwu Zhou, Canran Wang, Qingzhi Wu, Li Ren, Jixiang Zhu, Songsong Zhu, Peyton Tebon, Wujin Sun and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced healthcare materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Moyuan QuDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Xing JiangDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Xingwu ZhouDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Canran WangDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Qingzhi WuDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Li RenDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Jixiang ZhuDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Songsong ZhuState Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China.
Peyton TebonDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Wujin SunDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Ali KhademhosseiniDepartment of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics (C-MIT) University of California, Los Angeles, Los Angeles, CA, 90095, USA.ORCID 0000-0001-6322-8852
California NanoSystems Institute · USNanjing University of Chinese Medicine · CNSichuan University · CN

Funding

Microengineered Osteons for Bone Tissue EngineeringR01AR057837 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2010 to 2018
$5.1M
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the HipR01AR072613 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B, YANG, YUNZHI · 2018 to 2022
$2.2M
3D printed muscle-bone organ implant for treating large injuriesR01AR073135 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, JANG, HAE LIN · 2018 to 2022
$2.2M
Rapid 3D bioprinting of biomimetic vascularized tissue constructsR01EB021857 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, DOKMECI, MEHMET REMZI · 2016 to 2019
$2.1M
High-Throughput Microenvironment Regulation for ChondrogenesisR01AR066193 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALSBERG, EBEN, KHADEMHOSSEINI, ALI · 2015 to 2020
$2.1M
Multifunctional dressing for treatment of diabetic woundsR01GM126831 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI DOKMECI, MEHMET REMZI, TAMAYOL, ALI · 2018 to 2021
$1.3M
NIAMS NIH HHS R01 AR057837NIAMS NIH HHS R01 AR066193NIAMS NIH HHS R01 AR072613NIAMS NIH HHS R01 AR073135NIBIB NIH HHS R01 EB021857NIGMS NIH HHS R01 GM126831
6 · The paper itself

Abstract

Growth factors (GFs) play a crucial role in directing stem cell behavior and transmitting information between different cell populations for tissue regeneration. However, their utility as therapeutics is limited by their short half-life within the physiological microenvironment and significant side effects caused by off-target effects or improper dosage. "Smart" materials that can not only sustain therapeutic delivery over a treatment period but also facilitate on-demand release upon activation are attracting significant interest in the field of GF delivery for tissue engineering. Three properties are essential in engineering these "smart" materials: 1) the cargo vehicle protects the encapsulated therapeutic; 2) release is targeted to the site of injury; 3) cargo release can be modulated by disease-specific stimuli. The aim of this review is to summarize the current research on stimuli-responsive materials as intelligent vehicles for controlled GF delivery; Five main subfields of tissue engineering are discussed: skin, bone and cartilage, muscle, blood vessel, and nerve. Challenges in achieving such "smart" materials and perspectives on future applications of stimuli-responsive GF delivery for tissue regeneration are also discussed.

Indexed as

Drug Delivery SystemsTissue EngineeringIntercellular Signaling Peptides and ProteinsWound HealingIntercellular Signaling Peptides and Proteinsgrowth factorsregenerative medicinestimuli-responsive deliverytissue engineering

Identifiers

PMID32125786
PMCPMC7189772
OpenAlexW3009525672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.